Detailed information on these datasets was provided in Supplementary Table S1
Prior to March 19, 2025, compounding pharmacies could produce tirzepatide and provide it to weight loss & wellness centers and to medical spas like ours
When it does this, it helps raise your metabolism
The global obesity drug market is anticipated to reach $150 billion by 2035, driven by GLP-1 receptor agonists
Medicare would cover semaglutide when it was prescribed as Ozempic for type 2 diabetes, but it would not cover the same molecule, at a different dose, under the brand name Wegovy for obesity
Furthermore, the difference in efficacy of weight reduction between the 2 agents may become even greater with more prolonged use of teratrutide beyond 48 weeks